Financial Analysis: Myriad Genetics (MYGN) vs. Alphatec Holdings (ATEC)
Myriad Genetics (NASDAQ: MYGN) and Alphatec Holdings (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitabiliy, valuation, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
20.8% of Alphatec Holdings shares are held by institutional investors. 6.2% of Myriad Genetics shares are held by company insiders. Comparatively, 34.9% of Alphatec Holdings shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Myriad Genetics and Alphatec Holdings, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Myriad Genetics currently has a consensus price target of $21.83, indicating a potential downside of 9.63%. Given Myriad Genetics’ higher possible upside, research analysts plainly believe Myriad Genetics is more favorable than Alphatec Holdings.
Earnings & Valuation
This table compares Myriad Genetics and Alphatec Holdings’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Myriad Genetics||$757.30 million||2.17||$122.60 million||$0.45||53.69|
Myriad Genetics has higher revenue and earnings than Alphatec Holdings. Alphatec Holdings is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
This table compares Myriad Genetics and Alphatec Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Myriad Genetics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Alphatec Holdings has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
Myriad Genetics beats Alphatec Holdings on 7 of the 10 factors compared between the two stocks.
About Myriad Genetics
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
About Alphatec Holdings
Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.